Page last updated: 2024-12-10

onapristone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

onapristone: induces vaginal bleeding and luteal regression in monkeys; structure given in first source; progesterone antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5311505
CHEMBL ID1908373
SCHEMBL ID8740
MeSH IDM0150856

Synonyms (46)

Synonym
zk98299
zk299
gtpl2882
ivv-1001
zk-98299
zk 299
zk 98299
estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(3-hydroxypropyl)-, (11-beta,13-alpha,17-alpha)-
onapristonum [latin]
11beta-(p-(dimethylamino)phenyl)-17alpha-hydroxy-17-(3-hydroxypropyl)-13alpha-estra-4,9-dien-3-one
onapristone [inn]
zk-299
onapristona [spanish]
ccris 6530
zk 98.299
onapristone
(8s,11r,13r,14s,17s)-11-(4-dimethylaminophenyl)-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
D09571
onapristone (inn)
96346-61-1
unii-h6h7g23o3n
onapristonum
onapristona
h6h7g23o3n ,
xe 299
bdbm50366558
CHEMBL1908373
onapristone [who-dd]
11.beta.-(p-(dimethylamino)phenyl)-17.alpha.-hydroxy-17-(3-hydroxypropyl)-13.alpha.-estra-4,9-dien-3-one
onapristone [mi]
AKOS025311420
SCHEMBL8740
DTXSID90242210
HY-106389
CS-0025702
DB12637
(8s,11r,13r,14s,17s)-11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-6,7,8,11,12,13,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3(2h)-one
(8s,11r,13r,14s,17s)-11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-3-one
Q27088181
tetrafluoroethylene dimethylamine
(8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
nsc792824
nsc-792824
BO161274
estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-, (11.beta.,13.alpha.,17.alpha.)-
EX-A8027

Research Excerpts

Overview

Onapristone is a full progesterone receptor antagonist originally developed as an oral contraceptive. It is under investigation for use in endometrial, ovarian and prostate cancers.

ExcerptReferenceRelevance
"Onapristone is a full progesterone receptor antagonist originally developed as an oral contraceptive and later evaluated in phase II studies for metastatic breast cancer."( Onapristone Extended Release: Safety Evaluation from Phase I-II Studies with an Emphasis on Hepatotoxicity.
Bexon, AS; Campone, M; Cottu, PH; Dick, E; Italiano, A; Lehr, M; Lewis, JH; Rencher, W; Shearer, T; Varga, A, 2020
)
2.72
"Onapristone is a type I progesterone receptor (PR) antagonist, which prevents PR- mediated DNA transcription. "( Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.
Berton-Rigaud, D; Bexon, AS; Bonneterre, J; Bosq, J; Campone, M; Cottu, PH; Dieras, V; Floquet, A; Gilles, EM; Italiano, A; Jackson, DM; Leary, A; Lesoin, A; Lhomme, C; Lokiec, FM; Proniuk, S; Rezai, K; Sablin, MP; Varga, A; Zukiwski, A, 2018
)
2.26
"Onapristone is an antiprogestin with activity in breast cancer and is under investigation for use in endometrial, ovarian and prostate cancers. "( A single-dose PK study of onapristone including the effect of food on absorption.
Bexon, A; Chassard, D; Denot, C; Gilles, E; Lokiec, F; Patat, A; Proniuk, S; Ramos, HL; Rezai, K; Zukiwski, A, 2015
)
2.16
"Onapristone is a progesterone antagonist which inhibits the growth of mammary tumours in mice. "( The effect of onapristone, a progesterone antagonist, on the growth of human gastrointestinal cancer xenografts.
Ellis, IO; Hardcastle, JD; Jacobs, E; Robertson, JF; Watson, SA, 1997
)
2.1

Treatment

ExcerptReferenceRelevance
"Treatment with onapristone retarded the development of secretory changes within the endometrium without affecting the length of the luteal phase."( The effects of post-ovulatory administration of onapristone on the developmnent of a secretory endometrium.
Baird, DT; Buckley, CH; Cameron, ST; Chard, T; Critchley, HO; Kelly, RW, 1996
)
0.89

Pharmacokinetics

ExcerptReferenceRelevance
" Whether LIL and ONA share these latter two characteristics with MIF has not yet been determined but they illustrate properties that, in addition to diminished antiglucocorticoid activities and altered pharmacokinetic characteristics, warrant consideration during the development of these and never antiprogestational agents."( Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use.
Benet, LZ; Jang, GR, 1997
)
0.3

Compound-Compound Interactions

The effectiveness of mifepristone, onapristone and ORG 31806 alone or in combination with anordiol to terminate pregnancy in the rat was evaluated.

ExcerptReferenceRelevance
" In the combination with ON, ICI reversed the effect of ON on the progesterone level without influencing the luteinizing hormone and prolactin levels."( Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384.
Michna, H; Nishino, Y; Schneider, MR, 1994
)
0.53
"The effectiveness of mifepristone, onapristone, and ORG 31806 alone or in combination with anordiol to terminate pregnancy in the rat was evaluated."( Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat.
Bardin, CW; Dao, B; Koide, SS; Li, XJ; Vanage, G, 1997
)
0.57
"The pregnancy termination potency of varying doses of mifepristone, onapristone, and ORG 3806--alone and in combination with the estrogenic/antiestrogenic compound anordiol--was evaluated in adult rats."( Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat.
Bardin, CW; Dao, B; Koide, SS; Li, XJ; Vanage, G, 1997
)
0.53
" Rats bearing DMBA- or NMU-induced mammary tumors were treated with ON or MEG either alone or in combination with TAM for four weeks."( Potentiation of the antitumor effect of tamoxifen by combination with the antiprogestin onapristone.
Hirtreiter, C; Ishibashi, K; Nishino, T; Nishino, Y, 2009
)
0.58

Dosage Studied

The study was conducted in light of renewed interest in antiprogestin therapy for treating progesterone receptor-positive breast and gynecologic cancers. Twelve healthy female subjects received 10mg of oral IR onapristone after an overnight fast, or within 30 min of a high-fat, high-calorie meal.

ExcerptRelevanceReference
"299 and [3H]progesterone showed specific binding in the myometrial cytosol and the binding of each radiolabelled ligand could be displaced with the respective ligand in a dose-response manner."( Antiprogestin ZK-98.299 and progesterone display differential binding characteristics in the human myometrial cytosol.
D'souza, A; Hinduja, IN; Puri, CP, 1992
)
0.28
" Twelve healthy female subjects received 10 mg of oral IR onapristone after an overnight fast, or within 30 min of a high-fat, high-calorie meal with a 2-week washout between dosing periods."( A single-dose PK study of onapristone including the effect of food on absorption.
Bexon, A; Chassard, D; Denot, C; Gilles, E; Lokiec, F; Patat, A; Proniuk, S; Ramos, HL; Rezai, K; Zukiwski, A, 2015
)
0.96
" Twice-daily dosing of an extended-release formulation of onapristone was developed and clinically evaluated in light of renewed interest in antiprogestin therapy for treating progesterone receptor-positive breast and gynecologic cancers."( Onapristone Extended Release: Safety Evaluation from Phase I-II Studies with an Emphasis on Hepatotoxicity.
Bexon, AS; Campone, M; Cottu, PH; Dick, E; Italiano, A; Lehr, M; Lewis, JH; Rencher, W; Shearer, T; Varga, A, 2020
)
2.25
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glucocorticoid receptorHomo sapiens (human)Potency0.02700.00080.01390.0270AID74238
Androgen receptorHomo sapiens (human)Potency0.26900.00500.13700.2690AID39151
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorHomo sapiens (human)IC50 (µMol)1.00000.00000.723732.7000AID68887; AID68892
Estrogen receptorHomo sapiens (human)Ki0.02000.00000.42297.9070AID68900
Glucocorticoid receptorHomo sapiens (human)IC50 (µMol)0.02700.00000.495310.0000AID74091; AID74213; AID74215
Glucocorticoid receptorHomo sapiens (human)Ki0.04180.00010.38637.0010AID74220
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)0.00270.00032.177410.0000AID162121; AID162136
Progesterone receptorHomo sapiens (human)IC50 (µMol)0.00260.00000.580710.0000AID162121; AID162129; AID162136; AID162269; AID162600; AID32841
Progesterone receptorHomo sapiens (human)Ki0.01800.00030.03160.3997AID162283; AID162288; AID162293; AID162299; AID162470
Mineralocorticoid receptor Homo sapiens (human)IC50 (µMol)0.82330.00030.748410.0000AID126275; AID126279; AID126281
Androgen receptorHomo sapiens (human)IC50 (µMol)0.26900.00000.875310.0000AID38990; AID38993; AID38997
Androgen receptorHomo sapiens (human)Ki0.10000.00020.42407.2000AID39011
Estrogen receptor betaHomo sapiens (human)IC50 (µMol)1.00000.00010.529432.7000AID68887; AID68892
Estrogen receptor betaHomo sapiens (human)Ki0.02000.00000.12512.8760AID68900
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Progesterone receptorHomo sapiens (human)EC50 (µMol)3.33460.00010.40478.2000AID161790; AID161793; AID161798
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (122)

Processvia Protein(s)Taxonomy
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
regulation of gluconeogenesisGlucocorticoid receptorHomo sapiens (human)
chromatin organizationGlucocorticoid receptorHomo sapiens (human)
regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
apoptotic processGlucocorticoid receptorHomo sapiens (human)
chromosome segregationGlucocorticoid receptorHomo sapiens (human)
signal transductionGlucocorticoid receptorHomo sapiens (human)
glucocorticoid metabolic processGlucocorticoid receptorHomo sapiens (human)
gene expressionGlucocorticoid receptorHomo sapiens (human)
microglia differentiationGlucocorticoid receptorHomo sapiens (human)
adrenal gland developmentGlucocorticoid receptorHomo sapiens (human)
regulation of glucocorticoid biosynthetic processGlucocorticoid receptorHomo sapiens (human)
synaptic transmission, glutamatergicGlucocorticoid receptorHomo sapiens (human)
maternal behaviorGlucocorticoid receptorHomo sapiens (human)
intracellular glucocorticoid receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
glucocorticoid mediated signaling pathwayGlucocorticoid receptorHomo sapiens (human)
positive regulation of neuron apoptotic processGlucocorticoid receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
astrocyte differentiationGlucocorticoid receptorHomo sapiens (human)
cell divisionGlucocorticoid receptorHomo sapiens (human)
mammary gland duct morphogenesisGlucocorticoid receptorHomo sapiens (human)
motor behaviorGlucocorticoid receptorHomo sapiens (human)
cellular response to steroid hormone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to glucocorticoid stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to dexamethasone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusGlucocorticoid receptorHomo sapiens (human)
neuroinflammatory responseGlucocorticoid receptorHomo sapiens (human)
positive regulation of miRNA transcriptionGlucocorticoid receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
ovulation from ovarian follicleProgesterone receptorHomo sapiens (human)
glandular epithelial cell maturationProgesterone receptorHomo sapiens (human)
regulation of DNA-templated transcriptionProgesterone receptorHomo sapiens (human)
signal transductionProgesterone receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayProgesterone receptorHomo sapiens (human)
cell-cell signalingProgesterone receptorHomo sapiens (human)
positive regulation of gene expressionProgesterone receptorHomo sapiens (human)
negative regulation of gene expressionProgesterone receptorHomo sapiens (human)
paracrine signalingProgesterone receptorHomo sapiens (human)
negative regulation of phosphorylationProgesterone receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
lung alveolus developmentProgesterone receptorHomo sapiens (human)
regulation of epithelial cell proliferationProgesterone receptorHomo sapiens (human)
progesterone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
maintenance of protein location in nucleusProgesterone receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisProgesterone receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
signal transductionMineralocorticoid receptor Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionMineralocorticoid receptor Homo sapiens (human)
regulation of transcription by RNA polymerase IIMineralocorticoid receptor Homo sapiens (human)
intracellular steroid hormone receptor signaling pathwayMineralocorticoid receptor Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
MAPK cascadeAndrogen receptorHomo sapiens (human)
in utero embryonic developmentAndrogen receptorHomo sapiens (human)
regulation of systemic arterial blood pressureAndrogen receptorHomo sapiens (human)
epithelial cell morphogenesisAndrogen receptorHomo sapiens (human)
transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
signal transductionAndrogen receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAndrogen receptorHomo sapiens (human)
cell-cell signalingAndrogen receptorHomo sapiens (human)
spermatogenesisAndrogen receptorHomo sapiens (human)
single fertilizationAndrogen receptorHomo sapiens (human)
positive regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
negative regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
positive regulation of gene expressionAndrogen receptorHomo sapiens (human)
male somatic sex determinationAndrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
intracellular receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
Leydig cell differentiationAndrogen receptorHomo sapiens (human)
multicellular organism growthAndrogen receptorHomo sapiens (human)
positive regulation of phosphorylationAndrogen receptorHomo sapiens (human)
positive regulation of MAPK cascadeAndrogen receptorHomo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of cell differentiationAndrogen receptorHomo sapiens (human)
negative regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIIAndrogen receptorHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
regulation of developmental growthAndrogen receptorHomo sapiens (human)
animal organ formationAndrogen receptorHomo sapiens (human)
male genitalia morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell proliferationAndrogen receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationAndrogen receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityAndrogen receptorHomo sapiens (human)
activation of prostate induction by androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
morphogenesis of an epithelial foldAndrogen receptorHomo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
prostate gland growthAndrogen receptorHomo sapiens (human)
prostate gland epithelium morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell differentiation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
mammary gland alveolus developmentAndrogen receptorHomo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
cellular response to steroid hormone stimulusAndrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusAndrogen receptorHomo sapiens (human)
cellular response to testosterone stimulusAndrogen receptorHomo sapiens (human)
seminiferous tubule developmentAndrogen receptorHomo sapiens (human)
non-membrane-bounded organelle assemblyAndrogen receptorHomo sapiens (human)
positive regulation of miRNA transcriptionAndrogen receptorHomo sapiens (human)
regulation of protein localization to plasma membraneAndrogen receptorHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayAndrogen receptorHomo sapiens (human)
male gonad developmentAndrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayAndrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
signal transductionEstrogen receptor betaHomo sapiens (human)
cell-cell signalingEstrogen receptor betaHomo sapiens (human)
negative regulation of cell growthEstrogen receptor betaHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptor betaHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptor betaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (45)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
core promoter sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activityGlucocorticoid receptorHomo sapiens (human)
RNA bindingGlucocorticoid receptorHomo sapiens (human)
nuclear receptor activityGlucocorticoid receptorHomo sapiens (human)
nuclear glucocorticoid receptor activityGlucocorticoid receptorHomo sapiens (human)
steroid bindingGlucocorticoid receptorHomo sapiens (human)
protein bindingGlucocorticoid receptorHomo sapiens (human)
zinc ion bindingGlucocorticoid receptorHomo sapiens (human)
TBP-class protein bindingGlucocorticoid receptorHomo sapiens (human)
protein kinase bindingGlucocorticoid receptorHomo sapiens (human)
identical protein bindingGlucocorticoid receptorHomo sapiens (human)
Hsp90 protein bindingGlucocorticoid receptorHomo sapiens (human)
steroid hormone bindingGlucocorticoid receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingGlucocorticoid receptorHomo sapiens (human)
estrogen response element bindingGlucocorticoid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
transcription coactivator bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
DNA bindingProgesterone receptorHomo sapiens (human)
nuclear steroid receptor activityProgesterone receptorHomo sapiens (human)
G protein-coupled receptor activityProgesterone receptorHomo sapiens (human)
steroid bindingProgesterone receptorHomo sapiens (human)
protein bindingProgesterone receptorHomo sapiens (human)
zinc ion bindingProgesterone receptorHomo sapiens (human)
enzyme bindingProgesterone receptorHomo sapiens (human)
identical protein bindingProgesterone receptorHomo sapiens (human)
ATPase bindingProgesterone receptorHomo sapiens (human)
estrogen response element bindingProgesterone receptorHomo sapiens (human)
nuclear receptor activityProgesterone receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificMineralocorticoid receptor Homo sapiens (human)
DNA-binding transcription factor activityMineralocorticoid receptor Homo sapiens (human)
nuclear steroid receptor activityMineralocorticoid receptor Homo sapiens (human)
steroid bindingMineralocorticoid receptor Homo sapiens (human)
protein bindingMineralocorticoid receptor Homo sapiens (human)
zinc ion bindingMineralocorticoid receptor Homo sapiens (human)
TBP-class protein bindingMineralocorticoid receptor Homo sapiens (human)
sequence-specific double-stranded DNA bindingMineralocorticoid receptor Homo sapiens (human)
nuclear receptor activityMineralocorticoid receptor Homo sapiens (human)
estrogen response element bindingMineralocorticoid receptor Homo sapiens (human)
transcription cis-regulatory region bindingAndrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
RNA polymerase II general transcription initiation factor bindingAndrogen receptorHomo sapiens (human)
transcription coactivator bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
chromatin bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityAndrogen receptorHomo sapiens (human)
nuclear receptor activityAndrogen receptorHomo sapiens (human)
G protein-coupled receptor activityAndrogen receptorHomo sapiens (human)
signaling receptor bindingAndrogen receptorHomo sapiens (human)
steroid bindingAndrogen receptorHomo sapiens (human)
androgen bindingAndrogen receptorHomo sapiens (human)
protein bindingAndrogen receptorHomo sapiens (human)
beta-catenin bindingAndrogen receptorHomo sapiens (human)
zinc ion bindingAndrogen receptorHomo sapiens (human)
enzyme bindingAndrogen receptorHomo sapiens (human)
ATPase bindingAndrogen receptorHomo sapiens (human)
molecular adaptor activityAndrogen receptorHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingAndrogen receptorHomo sapiens (human)
POU domain bindingAndrogen receptorHomo sapiens (human)
molecular condensate scaffold activityAndrogen receptorHomo sapiens (human)
estrogen response element bindingAndrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptor betaHomo sapiens (human)
DNA bindingEstrogen receptor betaHomo sapiens (human)
nuclear steroid receptor activityEstrogen receptor betaHomo sapiens (human)
nuclear receptor activityEstrogen receptor betaHomo sapiens (human)
steroid bindingEstrogen receptor betaHomo sapiens (human)
protein bindingEstrogen receptor betaHomo sapiens (human)
zinc ion bindingEstrogen receptor betaHomo sapiens (human)
enzyme bindingEstrogen receptor betaHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptor betaHomo sapiens (human)
estrogen response element bindingEstrogen receptor betaHomo sapiens (human)
receptor antagonist activityEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleoplasmGlucocorticoid receptorHomo sapiens (human)
cytoplasmGlucocorticoid receptorHomo sapiens (human)
mitochondrial matrixGlucocorticoid receptorHomo sapiens (human)
centrosomeGlucocorticoid receptorHomo sapiens (human)
spindleGlucocorticoid receptorHomo sapiens (human)
cytosolGlucocorticoid receptorHomo sapiens (human)
membraneGlucocorticoid receptorHomo sapiens (human)
nuclear speckGlucocorticoid receptorHomo sapiens (human)
synapseGlucocorticoid receptorHomo sapiens (human)
chromatinGlucocorticoid receptorHomo sapiens (human)
protein-containing complexGlucocorticoid receptorHomo sapiens (human)
plasma membraneProgesterone receptorHomo sapiens (human)
nucleoplasmProgesterone receptorHomo sapiens (human)
mitochondrial outer membraneProgesterone receptorHomo sapiens (human)
cytosolProgesterone receptorHomo sapiens (human)
chromatinProgesterone receptorHomo sapiens (human)
nucleusProgesterone receptorHomo sapiens (human)
nucleoplasmMineralocorticoid receptor Homo sapiens (human)
endoplasmic reticulum membraneMineralocorticoid receptor Homo sapiens (human)
cytosolMineralocorticoid receptor Homo sapiens (human)
chromatinMineralocorticoid receptor Homo sapiens (human)
receptor complexMineralocorticoid receptor Homo sapiens (human)
nucleusMineralocorticoid receptor Homo sapiens (human)
plasma membraneAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
nucleoplasmAndrogen receptorHomo sapiens (human)
cytoplasmAndrogen receptorHomo sapiens (human)
cytosolAndrogen receptorHomo sapiens (human)
nuclear speckAndrogen receptorHomo sapiens (human)
chromatinAndrogen receptorHomo sapiens (human)
protein-containing complexAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
nucleoplasmEstrogen receptor betaHomo sapiens (human)
mitochondrionEstrogen receptor betaHomo sapiens (human)
intracellular membrane-bounded organelleEstrogen receptor betaHomo sapiens (human)
chromatinEstrogen receptor betaHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (70)

Assay IDTitleYearJournalArticle
AID126143Efficacy as percent inhibition of Mineralocorticoid receptor with aldosterone EC501998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore.
AID126279Inhibition of antagonist activity towards mineralocorticoid receptor (hMR)2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
AID162103Percent inhibition of transcriptional activity in human progesterone receptor using cotransfection assay in CV-1 cells observed at an EC50 concentration of progesterone (2.9+/-0.9)2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID73783Antagonist efficacy for glucocorticoid receptor2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
AID126275Inhibitory activity against human mineralocorticoid receptor (hMR)1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID126137Antagonist efficacy for mineralocorticoid receptor (hMR)2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
AID161960Efficacy at human progesterone receptor in CV-1 cells.2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
AID162269Antagonist activity against human progesterone receptor (hPR) using cotransfection assay in CV-1 cells2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID162600Concentration required to give half-maximal inhibition against human Progesterone receptor B isoform in co-transfected CV-1 cell lines.1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID126140Antagonist efficacy as percent inhibition of aldosterone (EC50) binding to Mineralocorticoid receptor1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID74213Inhibition of antagonist activity towards glucocorticoid receptor2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
AID38826Efficacy as percent inhibition of Androgen receptor with DHT EC501998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore.
AID73918Percent inhibition of glucocorticoid receptor transcriptional activity at Dexamethasone EC502000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID38820Antagonist efficacy as percent inhibition of DHT (EC50) binding to Androgen receptor1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID161790Agonist activity was determined against hPR (human progesterone receptor) compared to that of progesterone (100%)1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.
AID162121In vitro antagonist activity against human progesterone receptor isoform B(hPR-B) in mammalian(CV-1) cells1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore.
AID161650Agonist efficacy for human progesterone receptor in T47D human breast cancer cell; not active (<20% efficacy and/or >10 mM potency)2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
AID39011Binding affinity for human Androgen receptor1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID68734Efficacy as percent inhibition of Estrogen receptor with estradiol EC501998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore.
AID74220Binding affinity was determined for human glucocorticoid receptor(hGR).1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID74215Cross-reactivity as binding to human glucocorticoid receptor (hGR)2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID162283Binding affinity against Baculovirus-Expressed hPR-A1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore.
AID161968Antagonist activity against hPR (human progesterone receptor) compared to that of progesterone (100%)1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.
AID73911Antagonist efficacy as percent inhibition of Dexamethasone (EC50) binding to Glucocorticoid receptor1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID38990Inhibitory activity against human Androgen receptor1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID162129Inhibition of human progesterone receptor activation in T47D human breast cancer cell.2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
AID68900Binding affinity for human estrogen receptor1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID73916Efficacy as percent inhibition of glucocorticoid receptor with EC50 Dexamethasone1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore.
AID161818Human progesterone receptor (hPR) agonist activity in T47D human breast cancer cell line; NA=not active2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID162288Binding affinity was determined against hPR-A (human progesterone receptor) using progesterone radioligand in competitive binding assay1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.
AID126284Antagonist activity against Mineralocorticoid receptor1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore.
AID68892Cross-reactivity as binding to human estrogen receptor (hER)2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID68729Antagonist efficacy as percent inhibition of estradiol (EC50) binding to human Estrogen Receptor1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID161976In vitro antagonist activity against human progesterone receptor isoform B(hPR-B) in mammalian(CV-1) cells as percent inhibition1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore.
AID162293Binding affinity at human progesterone receptor.2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
AID161962Efficacy at human progesterone receptor in T47D human breast cancer cell.2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
AID162597Agonistic efficacy relative to progesterone (100%) on Human Progesterone receptor B isoform in co-transfected CV-1 cell lines.1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID126145Percent inhibition of mineralocorticoid receptor transcriptional activity at aldosterone EC502000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID68887Inhibitory activity against human estrogen receptor1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID162470Binding affinity determined for human Progesterone receptor A isoform1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID38816Antagonist efficacy for Androgen receptor2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
AID39151Antagonist activity against steroid Androgen receptor1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore.
AID68890Inhibition of antagonist activity towards Estrogen receptor; Not active2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
AID161793Antagonist activity against hPR (human progesterone receptor) compared to that of progesterone (100%)1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.
AID162101Percent inhibition of transcriptional activity in human progesterone receptor using T47D human breast cancer cell line observed at an EC50 concentration of progesterone (1.8+/-0.3 nM)2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID161981Percent efficacy for human progesterone receptor (hPR) agonist activity in T47D human breast cancer cell line; NA=not active2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID161983Percent efficacy for human progesterone receptor (hPR) agonist activity using cotransfection assay in CV-1 cells.2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID32843Antagonistic efficacy to the progesterone receptor measured in the T-47D alkaline phosphatase assay1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID162602Antagonistic efficacy relative to progesterone on Human Progesterone receptor B isoform expressed in CV-1 cells1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID38993Inhibition of antagonist activity towards Androgen receptor2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
AID68912Antagonist activity against Estrogen receptor1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore.
AID68736Cross-reactivity as binding to human estrogen receptor (hER)2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID162136Antagonist activity against human progesterone receptor (hPR) in T47D human breast cancer cell line2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID161821Human progesterone receptor (hPR) agonist activity using cotransfection assay in CV-1 cells.2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID74091Inhibitory activity against human glucocorticoid receptor (hGR)1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID38997Cross-reactivity as binding to human androgen receptor (hAR)2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID161798Antagonistic activity at human progesterone receptor in CV-1 cells.2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
AID589115Mechanism based inhibition of human cytochrome P450 3A4 measured in vivo2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID161956Agonist activity determined against hPR (human progesterone receptor) compared to that of progesterone (100%)1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.
AID161785Effective concentration against human progesterone receptor in T47D human breast cancer cell; not active (<20% efficacy and/or >10 mM potency)2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
AID74238Antagonist activity against Glucocorticoid receptor1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore.
AID32841Antagonistic potency to the human progesterone receptor measured in the T-47D alkaline phosphatase assay1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID162299Binding affinity against human progesterone receptor (hPR) in a competitive binding assay2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID38835Percent inhibition of transcriptional activity for androgen receptor compared to DHT at EC502000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID243422log (1/Km) value for human liver microsome cytochrome P450 3A42005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID126281Cross-reactivity as binding to human mineralocorticoid receptor (hMR)2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.
AID68727Antagonist efficacy for Estrogen receptor; Not active2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
AID1346849Human Glucocorticoid receptor (3C. 3-Ketosteroid receptors)2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
AID1346851Human Progesterone receptor (3C. 3-Ketosteroid receptors)1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
AID1346902Human Mineralocorticoid receptor (3C. 3-Ketosteroid receptors)2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (245)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (5.71)18.7374
1990's154 (62.86)18.2507
2000's56 (22.86)29.6817
2010's19 (7.76)24.3611
2020's2 (0.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.17 (24.57)
Research Supply Index5.55 (2.92)
Research Growth Index5.47 (4.65)
Search Engine Demand Index37.86 (26.88)
Search Engine Supply Index1.89 (0.95)

This Compound (31.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (1.58%)5.53%
Reviews17 (6.72%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other232 (91.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Clinical Trial Evaluating the Combination of Onapristone With Anastrozole for Women With Refractory Hormone Receptor Positive Endometrial Cancer [NCT04719273]Phase 214 participants (Actual)Interventional2021-01-28Active, not recruiting
ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study With Letrozole, Palbociclib and Onapristone ER [NCT04872608]Phase 10 participants (Actual)Interventional2021-09-09Withdrawn(stopped due to The sponsor closed the study due to discontinuing their onapristone program)
A Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer [NCT02049190]Phase 1/Phase 275 participants (Anticipated)Interventional2014-02-28Recruiting
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers [NCT02052128]Phase 1/Phase 260 participants (Anticipated)Interventional2014-01-31Recruiting
An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor-Positive, Progesterone Receptor-Positive, HER2-negative Advanced or Metastatic Breast Cancer (ELONA) [NCT05618613]Phase 1/Phase 267 participants (Anticipated)Interventional2022-12-02Active, not recruiting
A Window of Opportunity Trial of Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor-Positive and HER2-negative Breast Cancer [NCT04142892]Early Phase 110 participants (Actual)Interventional2020-11-06Completed
A Phase II Trial of OnapriStone in CoMbInation With FuLvestrant for Patients With ER-positive, and HER2-negative Metastatic Breast Cancer After Progression on Endocrine Therapy and CDK 4/6 Inhibitors [NCT04738292]Phase 211 participants (Actual)Interventional2021-10-05Terminated(stopped due to funding)
Basket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor), Alone or In Combination With Anastrozole in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endomet [NCT03909152]Phase 234 participants (Actual)Interventional2019-05-02Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]